Recently, cell culture systems producing hepatitis C virus particles (HCVcc) were developed. Establishment of serum-free culture conditions is expected to facilitate development of a whole-virus inactivated HCV vaccine. We describe generation of genotype 1-6 serum-free HCVcc (sf-HCVcc) from Huh7.5 hepatoma cells cultured in adenovirus expression medium. Compared to HCVcc, sf-HCVcc showed 0.6-2.1 log 10 higher infectivity titers (4.7-6.2 log 10 Focus Forming Units/mL), possibly due to increased release and specific infectivity of sf-HCVcc. In contrast to HCVcc, sf-HCVcc had a homogeneous singlepeak density profile. Entry of sf-HCVcc depended on HCV co-receptors CD81, LDLr, and SR-BI, and clathrin-mediated endocytosis. HCVcc and sf-HCVcc were neutralized similarly by chronic-phase patient sera and by human monoclonal antibodies targeting conformational epitopes. Thus, we developed serum-free culture systems producing high-titer single-density sf-HCVcc, showing similar biological properties as HCVcc. This methodology has the potential to advance HCV vaccine development and to facilitate biophysical studies of HCV.
Introduction
Hepatitis C virus (HCV) is a major public healthcare burden with 3-4 million new infections occurring each year and more than 150 million individuals estimated to be chronically infected worldwide (Fauvelle et al., 2013) . Many of these individuals develop serious chronic liver diseases such as cirrhosis and hepatocellular carcinoma, making HCV the most frequent cause of liver transplantation (Alter and Seeff, 2000) .
HCV is an enveloped, positive-stranded RNA virus of the genus Hepacivirus within the Flaviviridae family. Due to a high degree of genetic heterogeneity, HCV has been classified into 6 epidemiologically important genotypes and numerous subtypes, differing in approximately 30% and 20% of their nucleotide and amino acid sequence, respectively (Simmonds et al., 2005; Gottwein and Bukh, 2008) . Genotypes show important clinical and biological differences (Amoroso et al., 1998; Cross et al., 2010; Prentoe et al., 2011; Scheel et al., 2012; Sarrazin et al., 2012; Scheel and Rice, 2013) . Serotypes have not been defined; however, different genotypes and subtypes show differential sensitivity to neutralizing antibodies found in sera of chronically infected patients and to monoclonal neutralizing antibodies with therapeutic potential Abbreviations: AEM, adenovirus expression medium; ApoB, ApoCI, ApoE, apolipoprotein B, CI, E; BSA, bovine serum albumin; HCVcc, cell culture produced hepatitis C virus; FBS, fetal bovine serum; FFU, Focus Forming Units; HCV, hepatitis C virus; HRP, horseradish peroxidase; HVR1, hypervariable region 1; LVP, lipo-viroparticle; LDLr, low-density-lipoprotein receptor; B max , maximum blocking rate; IC 50 , median inhibitory concentration; MOI, multiplicity of infection; NS protein, nonstructural protein; ND, not determinable; BSK, PBS þ1% BSAþ0.2% skim milk; PE, phycoerythrin; RCF, relative centrifugal force; RT, room temperature; SR-BI, scavenger receptor class B type I; sf-HCVcc, serum-free cell culture produced hepatitis C virus; SEM, standard error of the mean; VLDL, very-low-densitylipoprotein n Corresponding author at: Copenhagen Hepatitis C Program (CO-HEP), Depart- (Meunier et al., 2005; Jensen et al., 2008; Gottwein et al., 2009; Prentoe et al., 2011; Giang et al., 2012) . The 9.6 kb HCV genome consists of 5ʹ and 3ʹ untranslated regions and a single open reading frame encoding structural proteins (Core, E1 and E2), the viroporin p7, and nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) . The HCV virion is believed to consist of a nucleocapsid of HCV Core proteins containing the genomic RNA, covered by a lipid envelope with the HCV envelope glycoproteins E1 and E2. The HCV life cycle is tightly linked to the hepatic lipid metabolism. During assembly and release, the HCV virion is believed to associate with very-low-density-lipoprotein (VLDL) or VLDL-like structures, creating lipo-viro-particles (LVP) (Popescu and Dubuisson, 2010; Felmlee et al., 2013) . Thus, HCV apparently circulates in infected patients associated to different classes of lipoproteins , resulting in a heterogeneous density profile apparent following buoyant density gradient ultracentrifugation (Nielsen et al., 2006; Felmlee et al., 2013) . Components of the VLDL assembly and secretion pathway, such as apolipoprotein E (ApoE), might be important for the association between HCV and lipoproteins (Chang et al., 2007) .
HCV entry is mediated by several co-receptors, including CD81, the low-density-lipoprotein receptor (LDLr) and the scavenger receptor class B type I (SR-BI) (Ploss and Evans, 2012) . While HCV is believed to interact directly with CD81 through E2 (Pileri et al., 1998; McKeating et al., 2004) , interactions with other receptors, such as LDLr and SR-BI, might occur through lipoprotein components present on the LVP, such as ApoE (Owen et al., 2009; Thi et al., 2012) , although direct interactions between E2 and SR-BI have also been reported (Scarselli et al., 2002; Thi et al., 2012) . Eventually, HCV is internalized through clathrin-mediated endocytosis (Blanchard et al., 2006; Meertens et al., 2006) .
There is no vaccine available for HCV. Current standard-of-care, based on pegylated interferon-α2 and ribavirin, has limited efficacy and is associated with severe side effects and contraindications (Sarrazin et al., 2012) . Even though promising new compounds for treatment of HCV are being developed and licenced (Sarrazin et al., 2012; Scheel and Rice, 2013) , only a minority of HCV-infected individuals is expected to be diagnosed and treated, mainly due to the asymptomatic nature of infection, economic constraints and contraindications (Fauvelle et al., 2013) . Thus, an HCV vaccine is needed to control HCV globally. Most successful antiviral vaccines employ inactivated or attenuated whole viral particles as vaccine antigen and depend on the induction of neutralizing antibodies (Plotkin, 2008; Plotkin and Plotkin, 2011) . Due to a lack of HCV particle-producing cell culture systems, this approach was not feasible for HCV (Steinmann and Pietschmann, 2013; Lohmann and Bartenschlager, 2014) .
Only in 2005, the first HCV cell culture system supporting the full viral life cycle was developed, based on the genotype 2a isolate JFH1 and the human hepatoma cell line Huh7 and derived cell lines (Wakita et al., 2005; Lindenbach et al., 2005; Zhong et al., 2005) . Subsequently, culture systems producing HCV particles (HCVcc) of the major genotypes were developed using JFH1-based recombinants expressing genotype specific Core, E1, E2, p7 and NS2 (Pietschmann et al., 2006; Gottwein et al., 2007; Yi et al., 2007; Scheel et al., 2008; Jensen et al., 2008; Gottwein et al., 2009) . Such particles could serve as antigens in a whole-virus inactivated HCV vaccine primarily aiming at induction of neutralizing antibodies against structural proteins of the major HCV genotypes.
However, HCVcc yields from the developed cell culture systems are relatively low compared to quantities envisioned to be required for vaccine production. Further, as patient derived HCV particles (Nielsen et al., 2006) , HCVcc showed a heterogeneous density profile (Lindenbach et al., 2005; Lindenbach et al., 2006; Gastaminza et al., 2006; Prentoe et al., 2011) , making density-based purification and concentration procedures difficult. Also, cell cultures are typically treated with animal-derived trypsin, and growth medium used for production of HCVcc is typically supplemented with fetal bovine serum (FBS). Vaccine development, as well as other research applications, such as biophysical studies of HCV particle composition, require generation of purified and concentrated HCVcc stocks. This is expected to be facilitated by reducing concentrations of non-HCV proteins such as FBS derived proteins in HCVcc producing cell cultures. Further, use of FBS and animal-derived trypsin increases the risk of contamination with adventitious microbial agents, of relevance for HCV vaccine development (WHO, 1998; Houghton et al., 2013) . Thus, development of methods for production of HCVcc under serum-free conditions is a research focus. At the onset of this study it had been demonstrated that Huh7 cells could be cultured in serum-free medium (RPMI 1640 supplemented with Na 2 SeO 3 ) without previous adaptation for an extended period of time, and that serum-free cell cultures (DMEM supplemented with Na 2 SeO 3 and lipid rich albumin) allowed replication of HCV (Nakabayashi et al., 1982; Abe et al., 2007) .
In this study, we aimed at developing and characterizing serum-free genotype 1-6 HCVcc particles (sf-HCVcc). From infected Huh7.5 cell cultures maintained in adenovirus expression medium (AEM) without using trypsin, we were able to harvest genotype 1-6 sf-HCVcc containing culture supernatants. The sfHCVcc particles were characterized by increased infectivity titers and an altered density profile with a single infectivity peak, expected to facilitate density-based purification procedures. However, sf-HCVcc showed similar biological properties as HCVcc regarding routes of viral entry and susceptibility to neutralizing antibodies. Establishment of a robust methodology for generation of high-titer single-density serum-free HCVcc is expected to aid HCV vaccine development.
Results
Huh7.5 cells cultured in serum-free medium yield higher HCV infectivity titers than conventional cultures To produce sf-HCVcc, HCV recombinants were cultured in Huh7.5 cells maintained in AEM, a commercially available cell culture medium without animal or human serum as described in "Materials and methods" section. Because AEM cultured Huh7.5 cells did not tolerate detachment, AEM was replaced every 2-3 days without splitting the cells. Thus, animal-derived trypsin was not used during the virus production phase. Cultures handled in this manner became over-confluent but could be maintained for at least 29 days (data not shown).
We tested if AEM cultured cells supported production of sfHCVcc. Huh7.5 cells cultured in DMEMþ10% FBS were initially infected with JFH1-based Core-NS2 recombinants H77(1a), J4(1b), S52(3a) and ED43(4a) (Gottwein et al., 2009) (Fig. 1) . When viral infection had spread to $ 80% of culture cells, as determined by immunostaining of HCV NS5A antigen, one replicate culture was maintained in AEM and another in DMEMþ10% FBS. Similar to previous observations (Gottwein et al., 2009 ), HCVcc peak supernatant infectivity titers were 3.4-4.2 log 10 Focus Forming Units (FFU)/ml, followed by a drop in infectivity titers, when virus induced cell death was observed ( Fig. 1) (Gottwein et al., 2007) . For sf-HCVcc, peak infectivity titers were higher than for HCVcc, reaching 4.6-5.0 log 10 FFU/ml (Fig. 1) . Also, relatively high infectivity titers were maintained for a longer period for sf-HCVcc than for HCVcc.
We next aimed at producing sf-HCVcc virus stocks of prototype strains of the six major HCV genotypes and epidemiologically important subtype 1b for further characterization. We infected Huh7.5 cells cultured in DMEM þ10% FBS with Core-NS2 recombinants indicated in Fig. 2 . DMEM þ10% FBS was replaced by AEM, when 40-80% of culture cells were infected (Fig. 2) . From these cultures, high-titer sf-HCVcc virus stocks were harvested at four consecutive time points, before cultures were closed. Peak infectivity titers between 4.7 and 6.2 log 10 FFU/ml were observed for sf-HCVcc, with sf-J4(1b) and sf-ED43(4a) showing the lowest and sf-SA13(5a) showing the highest titers ( Fig. 2 and Table 1) . Thus, sf-HCVcc stocks showed 0.6-2.1 log 10 FFU/mL increased infectivity titers compared to previously described HCVcc reference stocks (Table 1) (Gottwein et al., 2009) . HCV RNA and Core titers for sf-HCVcc and HCVcc reference stocks were similar (Table 1) . Thus, genotype 1-6 sf-HCVcc showed increased specific infectivities compared to HCVcc reference stocks (Table 1) . This increase in specific infectivity was most pronounced for recombinants with comparatively low infectivity titers. Thus, based on RNA titers, specific infectivity was 20-fold increased for sf-J4(1b) and 40-fold increased for sf-ED43(4a) compared to their HCVcc counterparts (Table 1) . This resulted in differences in specific infectivity between sf-HCVcc of different genotypes being smaller than those between HCVcc of different genotypes. For sf-HCVcc, based on RNA titers, specific infectivities were between 1/40 FFU/IU and 1/631 FFU/IU, while HCVcc showed specific infectivities between 1/398 FFU/IU and 1/12,589 FFU/IU (Table 1) .
Higher infectivity titers of sf-HCVcc might be due to increased viral release and specific infectivity
We next aimed at determining if the observed differences in infectivity titers were due to the fact that DMEM þ10% FBS cultures were split at regular intervals, while AEM cultures were kept over-confluent. Huh7.5 cell cultures were infected with SA13(5a) and (i) maintained in DMEM þ 10% FBS and split every 2-3 days, (ii) maintained in DMEM þ10% FBS without splitting, or (iii) maintained in AEM without splitting (Fig. 3A) . The DMEM þ10% FBS culture yielded a peak infectivity titer of 5.6 log 10 FFU/ml, while the AEM culture yielded a peak infectivity titer of 6.1 log 10 FFU/ml (Fig. 3A) . However, the DMEM þ10% FBS culture maintained without splitting reached only 4.6 log 10 FFU/ mL (Fig. 3A) . This suggested that the high infectivity titers observed for the AEM cultures were not due to reduced stress related to avoiding cell culture splitting.
We subsequently investigated cell viability and proliferation of cells cultured in AEM versus DMEM þ10% FBS. After 48 h of culture in AEM, when increased infectivity titers were observed, cell viability and proliferation of AEM cultures was similar to that of DMEM þ10% FBS cultures (Fig. 3B) . Thus, changes in cell viability or proliferation did not explain the increased infectivity titers observed.
We further investigated, whether sf-HCVcc were more stable than HCVcc, which might contribute to the observed increase in infectivity titers. Up to 5 freeze/thaw cycles did not result in major decrease in infectivity or differences in infectivity for SA13(5a), sf-SA13(5a) or sf-SA13(5a) supplemented with 10% FBS (Fig. 3C ). Incubation for 48 h at 4 1C resulted in a minor decrease in infectivity of sf-SA13(5a) compared to SA13(5a) and sf-SA13(5a) supplemented with 10% FBS (Fig. 3D) . Incubation for 4-48 h at room temperature or 37 1C resulted in a gradual decrease in infectivity; this decrease was more pronounced for sf-SA13(5a) Fig. 1 . Serum-free Huh7.5 cell cultures produced high-titer sf-HCVcc. Huh7.5 cells were infected with the indicated JFH1-based Core-NS2 recombinants in DMEMþ 10% FBS for 18 h. Cells were split into two replicate DMEMþ 10% FBS cultures. When $ 80% of culture cells were infected, as determined by HCV NS5A immunostaining, one replicate culture was maintained in DMEMþ10% FBS (black bars), while the other replicate culture was maintained in AEM (gray bars). At the indicated day post infection, supernatants were collected and DMEMþ10% FBS cultures were split, while fresh medium was added to AEM cultures as described in "Materials and methods" section. Supernatant HCVcc infectivity titers are shown as means of 3 replicates with standard error of the mean (SEM). The lower limit of detection in the experiments shown was up to 2.7 log 10 FFU/ml, indicated by y-axis break.
n At this time point, the experiment consisted only of replicate cultures maintained in DMEMþ 10% FBS; only one culture was titrated.
than for SA13(5a), and partially rescued by addition of 10% FBS to sf-SA13(5a) (Fig. 3D) . Thus, FBS might result in stabilization of HCVcc. However, apparently, increased infectivity titers were not caused by increased stability of sf-HCVcc.
In order to investigate whether certain steps of the viral life cycle were affected by serum-free culture conditions, we carried out single-cycle virus production assays using CD81-deficient S29 cells, which are derived from Huh7.5 cells (Russell et al., 2008) . Following transfection with SA13(5a) HCV RNA, AEM cultures showed a $ 1 log decrease in intracellular HCV Core and infectivity titers compared to DMEM þ10% FBS cultures, indicating a decrease in viral replication/translation ( Fig. 4A and B) . In contrast, AEM and DMEM þ 10% FBS cultures showed similar extracellular Core titers, but AEM cultures had a $ 1 log increase in extracellular infectivity titers compared to DMEM þ10% FBS cultures. These findings suggest that AEM culture resulted in increased viral release and that sf-HCVcc had increased specific infectivity compared to HCVcc. Furthermore, for HCVcc, the peak extracellular infectivity titer was observed 48 h post transfection followed by a decrease at 72 h post transfection, while for sf-HCVcc high titers were observed at both time points (Fig. 4B ). This is in agreement with the prolonged peak of infection observed in Huh7.5 cells (Figs. 1-3 ).
Infectious sf-HCVcc particles displayed a homogeneous density profile
To investigate their biophysical properties we subjected sf-HCVcc (Fig. 2) to equilibrium buoyant density ultracentrifugation on iodixanol gradients. As described previously for genotypes 2a, 3a, 5a and 6a HCVcc (Lindenbach et al., 2005 ; Lindenbach et al., Fig. 2 . Generation of genotype 1-6 sf-HCVcc virus stocks. Huh7.5 cells were infected with the indicated viruses in DMEM þ10% FBS at an MOI of 0.003 for 6 h. On days 6-15 post infection, depending on the growth kinetics of the respective virus, when 40-80% of culture cells were infected, as determined by HCV NS5A immunostaining, DMEM þ10% FBS was replaced by AEM. At the indicated day post infection, supernatant was collected and fresh AEM was added to the cells. Supernatant HCVcc infectivity titers are shown as means of 3 replicates with standard error of the mean (SEM). Black bars represent DMEMþ 10% FBS supernatant HCVcc infectivity titers; gray bars represent AEM supernatant sf-HCVcc infectivity titers. The lower limit of detection in the experiments shown was up to 2.3 log 10 FFU/ml, indicated by y-axis break.
2006; Gastaminza et al., 2006; Prentoe et al., 2011) , we observed that infectious genotype 1-6 HCVcc particles constituted heterogeneous virus populations with buoyant densities between 1.01-1.10 g/mL (Fig. 5) . Interestingly, for genotype 1-6 sf-HCVcc harvested after 48 h of cell culture with AEM, we detected up to 92% of recovered infectious sf-HCVcc at a single density of $1.10 g/mL, following iodixanol gradient ultracentrifugation. Furthermore, between 71% and 97% of infectious sf-HCVcc could be recovered in three fractions with densities between 1.09 g/mL and 1.12 g/mL (Fig. 5) . Thus, infectious genotype 1-6 sf-HCVcc constituted a more homogeneous virus population compared to their HCVcc counterparts.
Infectious sf-HCVcc particles were apparently associated with ApoE
The altered density profile of sf-HCVcc might indicate an altered association with lipoproteins. To investigate if sf-HCVcc was associated with ApoE, a key component of HCV associated lipoproteins (Popescu and Dubuisson, 2010; Felmlee et al., 2013) , we carried out neutralization assays using a monoclonal antibody directed against ApoE (Weisgraber et al., 1983; Chang et al., 2007) . Due to limited availability of this antibody, we studied only the genotype 5a recombinant. SA13(5a) and sf-SA13(5a) showed a similar concentration-dependent response with median inhibitory concentrations (IC 50 ) of 1.3 mg/mL for SA13(5a) and 1.1 mg/mL for sf-SA13(5a), and almost complete neutralization achieved at the highest α-ApoE concentrations (Fig. 6A) , suggesting that genotype 5a HCVcc and sf-HCVcc showed similar association with ApoE. These data were confirmed by neutralizing SA13(5a) and sf-SA13 (5a) using anti-Apolipoprotein E antibody (ab24139, abcam). Using this polyclonal rabbit IgG, complete neutralization, as well as 50% neutralization, was observed at similar dilutions for SA13(5a) and sf-SA13(5a) (data not shown).
We further carried out immunoprecipitation of SA13(5a) and sf-SA13(5a) with the ApoE specific monoclonal antibody also used for neutralization experiments in Fig. 6A (Weisgraber et al., 1983; Chang et al., 2007) . We observed no major differences in the amount of viral RNA precipitated by this antibody (Fig. 6B) . Collectively, these data indicate that HCVcc and sf-HCVcc showed similar association with ApoE.
Establishment of the use of sf-HCVcc in biological assays
To further characterize sf-HCVcc, we aimed at studying routes of sf-HCVcc entry and sf-HCVcc sensitivity to neutralizing antibodies. To avoid potential in vitro association of sf-HCVcc with FBS components such as lipoproteins (Wünschmann et al., 2006) , we aimed at replacing DMEM þ10% FBS, typically used in such assays, by AEM during the viral infection step. However, using AEM, in initial experiments with genotypes 5a and 2a viruses, we found greatly reduced infectivity for sf-SA13(5a) and sf-J6(2a). Interestingly, SA13(5a) and J6(2a) infectivity was also reduced when these viruses were diluted in AEM prior to infection ( Fig. 7A and data not shown). This loss of infectivity was not due to down-regulation of important HCV co-receptors on AEM cultured Huh7.5 cells, since expression of CD81, LDLr, SR-BI and claudin-1 was similar in Huh7.5 cells cultured for three hours in either DMEM þ10% FBS or AEM, as determined by flow cytometry (Fig. 8) .
To determine how infectivity of sf-HCVcc in AEM could be rescued, we diluted sf-SA13(5a) in DMEM þ10% FBS (reference culture), DMEM, AEM, or AEM supplemented with 10% FBS and/or GlutaMax (a glutamine supplement present in DMEM þ 10% FBS culture medium but not in AEM). For sf-SA13(5a) diluted in AEM, infectivity was only 12% of infectivity of the reference culture (Fig. 7B ). While supplementing AEM with GlutaMax did not influence infectivity, supplementing AEM with 10% FBS or 10% FBS and GlutaMax increased infectivity of sf-SA13(5a) to 67% and 68% respectively, compared to the reference culture (Fig. 7B ). When sf-SA13(5a) was diluted in DMEM without FBS (GlutaMax only), infectivity was only 30% compared to the reference culture (Fig. 7B) . Apparently other FBS components than lipoproteins and lipoprotein-associated factors mediated this enhancement Serum-free cultures were infected and maintained as described in "Materials and methods" section ( Fig. 2) . For sf-HCVcc, supernatant HCV infectivity titers, Core antigen, and RNA titers were determined, and specific infectivities were calculated. Representative peak infectivity titers as well as Core and RNA titers from the same sample are shown. Core-E2 sequences were determined by direct sequence analysis as described in "Materials and methods" section. For sf-J6(2a), sf-S52(3a), sf-ED43(4a), sf-SA13(5a) and sf-HK6a(6a), Core-E2 sequences were identical to the plasmid sequence. The sf-H77(1a) had acquired the previously described amino acid change Y361H, estimated to be present in 50% of viral genomes; this change was also present in the H77(1a) HCVcc stock shown in this table (Gottwein et al., 2009 ). The sf-J4(1b) had acquired amino acid changes T578A and D584G, estimated to be present in the majority of viral genomes. For HCVcc, characteristics of references stocks are reproduced from Gottwein et al. (2009) . a Isolate and genotype of Core-NS2 of the used JFH1-based recombinants is indicated. Recombinants are further described in "Materials and methods" section. b For sf-HCVcc, supernatant infectivity titers were determined as FFU/mL by a cell culture-based titration assay as described in "Materials and methods" section. Values are means of three replicates. For HCVcc, values are reproduced from Gottwein et al. (2009) . c For sf-HCVcc, supernatant RNA titers were determined in the samples, for which infectivity titers are given, as IU/mL by TaqMan PCR as described in "Materials and methods" section. Values are means of two replicates. For HCVcc, values are reproduced from Gottwein et al. (2009) . d Core titers were determined in the samples, for which infectivity titers are given, as amol/mL using the ARCHITECT HCV Ag assay (Abbott). e For sf-HCVcc, specific infectivity was calculated as FFU/IU by dividing supernatant infectivity titers with the corresponding RNA titers. For HCVcc, values were adapted from Gottwein et al. (2009) to FFU/IU by dividing supernatant infectivity titers with the corresponding RNA titers. f Specific infectivity was calculated as FFU/amol Core by dividing supernatant infectivity titers with the corresponding Core titers. g The peak infectivity titer of this SA13(5a) reference stock was lower than what we typically observe. Typically, peak titers for SA13(5a) are $ 5 log 10 FFU/mL (Fig. 3A ).
of infectivity, because supplementing AEM with either VLDL, low density lipoprotein, high density lipoprotein, ApoB, ApoCI, ApoE or water-soluble cholesterol did not rescue infectivity, while lipoprotein deficient FBS partly restored infectivity (data not shown). Furthermore, we observed that sf-SA13(5a) infectivity correlated with the % of FBS in AEM (Fig. 7C ). These findings suggested that yet undefined factors in FBS culture medium supplement were crucial for infectivity of HCVcc and sf-HCVcc. Therefore, we investigated if sf-HCVcc was able to associate in vitro with FBS components, leading to alteration of the observed sfHCVcc density profile. We incubated sf-SA13(5a) with different media and serum concentrations in the absence of cells. Such incubations did not affect the density profile of sf-SA13(5a) (Fig. 9 ), suggesting that association between sf-HCVcc and serum components did not occur to an extent that influenced the previously observed density profile (Fig. 5 ). Thus, it was feasible to carry out further biological studies of sf-HCVcc in AEM supplemented with 10% FBS.
Entry of sf-HCVcc depended on HCV co-receptors CD81, LDLr and SR-BI as well as on clathrin-mediated endocytosis
To investigate if sf-HCVcc differed from HCVcc regarding entry into the host cell, we first studied HCV co-receptors LDLr and SR-BI, which might interact with lipoprotein components on the LVP (Owen et al., 2009; Thi et al., 2012) , as well as CD81, supposed to directly interact with E2 (Pileri et al., 1998; McKeating et al., 2004) . . Increased infectivity titers of serum-free cell cultures were not due to reduced cell-splitting, changes in cell viability or proliferation, or increased viral stability. (A) AEM cultures produced higher infectivity titers than DMEM þ10% FBS cultures handled similarly and DMEMþ 10% FBS control cultures. Huh7.5 cells were infected with the SA13(5a) JFH1-based Core-NS2 recombinant in DMEM þ 10% FBS for 3 h at an MOI of 0.003. On day 4 post-infection, cells were split into three replicate cultures. Following day 6 post infection, when $ 80% of culture cells were infected, as determined by HCV NS5A immunostaining, one replicate culture was maintained in DMEM þ10% FBS and split every 2-3 days, another replicate culture was maintained in DMEM þ10% FBS without being split, while the third replicate culture was maintained in AEM without being split. At the indicated days post infection, supernatants were collected. Supernatant HCVcc infectivity titers are shown as means of 3 replicates with standard error of the mean (SEM). The lower limit of detection in the experiment shown was up to 2.6 log 10 FFU/ml, indicated by y-axis break.
n The culture originally infected with SA13(5a) was first split into three replicates at day 4 post infection; thus, on days 1 and 4 post infection only one infectivity titer is shown. On day 6, DMEM þ 10% FBS supernatants were harvested from the three replicate cultures; subsequently cultures were maintained in the different growth media indicated. (B) AEM cultures showed similar viability and proliferation as DMEM þ 10% FBS cultures. Cell viability or proliferation of Huh7.5 cells cultured for 48 h in AEM versus DMEM þ 10% FBS was determined as described in "Materials and methods" section. The % viability/proliferation was calculated by relating absorbance at 490 nm (viability) or 450 nm (proliferation) determined for AEM cultures to the mean absorbance of 10 replicate DMEM þ10% FBS cultures. Bars represent the means of 10 replicates with SEM. (C) sf-HCVcc and HCVcc showed similar freeze-thaw stability. SA13(5a) diluted 1:100 in DMEM þ 10% FBS or sf-SA13(5a) diluted 1:100 in either AEM or AEMþ 10% FBS were exposed to up to 5 freeze/ thaw cycles. Samples were thawn at room temperature and frozen at À 80 1C. After the indicated number of cycles, infectivity titers were determined as described in "Materials and methods" section. The % infectivity was calculated by relating the infectivity titer of each sample to the mean titer of a reference sample of the same stock, which had been stored at À 80 1C. Bars represent the means of three replicates with SEM. (D) sf-HCVcc showed decreased stability under temperature stress. SA13(5a) diluted 1:100 in DMEM þ10% FBS or sf-SA13(5a) diluted 1:100 in either AEM or AEMþ10% FBS were incubated at 4 1C, room temperature (RT) or 37 1C for 4-48 h as indicated. Infectivity titers were determined as described in "Materials and methods" section. The % infectivity was calculated by relating the infectivity titer of each sample to the mean titer of a reference sample of the same stock, which had been stored at À 80 1C. Bars represent the means of three replicates with SEM. The lower limit of detection in the experiment shown was up to 2%, indicated by y-axis break.
When blocking CD81, for genotype 1-6 HCVcc, maximum blocking rates (B max ) of $ 100% were observed at the highest α-CD81 concentrations; for these viruses, similar blocking rates were previously observed (Gottwein et al., 2009) . Genotype 1-6 sfHCVcc showed similar concentration-dependent sensitivity towards CD81 blocking as their HCVcc counterparts (Fig. 10, left  column) .
When blocking LDLr, we found concentration-dependent blocking for genotype 1-6 HCVcc. B max values were between 69% for ED43(4a) and 100% for SA13(5a) at the highest concentrations of α-LDLr, suggesting genotype/isolate-specific differences in dependency on LDLr (Fig. 10, middle column) . Genotype 1-6 sf-HCVcc could also be blocked in a concentration-dependent manner, with B max values between 33% for sf-HK6a(6a) and 74% for sf-H77(1a) at the highest concentrations of α-LDLr. While sf-H77(1a), sf-S52(3a) and sf-ED43(4a) showed similar B max values as their HCVcc counterparts, sf-J4(1b), sf-J6(2a), sf-SA13(5a) and sf-HK6a(6a) showed 31-55% lower B max values than their HCVcc counterparts, suggesting that sf-HCVcc of certain genotypes had lower dependency on LDLr than their HCVcc counterparts.
Blocking of SR-BI had only limited effect on entry of J4(1b) and HK6a(6a) HCVcc with B max values o 50% (Fig. 10, right column) . For HCVcc of other genotypes we observed concentrationdependent blocking with B max values between 51% for J6(2a) and 80% for H77(1a) at the highest concentrations of α-SR-BI. Thus, sensitivity to SR-BI blocking apparently depended on the genotype/isolate. Blocking of SR-BI also had limited effect on entry of sf-J4(1b) and sf-HK6a(6a). Entry of sf-HCVcc of other genotypes was blocked in a concentration-dependent manner, with B max values between 60% for sf-SA13(5a) and 86% for sf-H77(1a). B max values were similar between HCVcc and sf-HCVcc of the same genotype. Thus, overall, HCVcc and sf-HCVcc of the same genotype showed similar sensitivity to SR-BI blocking.
Finally, we studied dependency of genotype 1-6 sf-HCVcc on clathrin-mediated endocytosis. When pre-treating cells with chlorpromazine, we observed concentration-dependent blocking rates of up to 93%, suggesting that both sf-HCVcc and HCVcc depended on clathrin-mediated endocytosis (Fig. 11A-G) . We were not able to achieve 100% blocking for any of the recombinants at 10 μg/mL chlorpromazine, the highest concentration not resulting in cytotoxic effects (Fig. 11H) . Interestingly, most sf-HCVcc were slightly more sensitive to chlorpromazine treatment than their HCVcc counterparts. This difference was greatest for J4(1b), ED43 (4a) and HK6a(6a). For J6(2a) and SA13(5a) no obvious difference was observed, while H77(1a) and S52(3a) showed relatively small differences. This suggested that dependency on clathrin-mediated endocytosis might be slightly greater for sf-HCVcc of most genotypes/isolates than for HCVcc.
In conclusion, these data suggest that, overall, entry of HCVcc and sf-HCVcc relied on CD81, LDLr and SR-BI HCV co-receptors as well as on clathrin-mediated endocytosis, with exception of genotype 1b and 6a particles, which could not be blocked by α-SR-BI. However, we detected minor differences for recombinants of different HCV genotypes and for HCVcc versus sf-HCVcc regarding dependency on certain receptors and clathrinmediated endocytosis Chronic-phase patient sera and monoclonal antibodies against conformational epitopes in E1E2 and E2 neutralized sf-HCVcc
To investigate if there were differences between HCVcc and sfHCVcc in sensitivity to neutralizing antibodies, we first did neutralization of genotype 1-6 viruses using serum from genotype 1a infected Patient H, taken 29 years after acute infection (H06 ). For HCVcc, as previously described, S52(3a) was the least sensitive to neutralization with H06 ( Fig. 12D ) Gottwein et al., 2009; Prentoe et al., 2011) . For HCVcc of other genotypes we observed dilution-dependent neutralization with IC 50 values ranging from 1/1,436 to 1/233,209 and relatively high neutralization rates by high concentrations of H06 serum (Fig. 12) . For genotype 1-6 sf-HCVcc, we found similar neutralization patterns as for their HCVcc counterparts. For all sfHCVcc except S52(3a) we observed dilution dependent neutralization with IC 50 values ranging from 1/605 to 1/156,666 and relatively high neutralization rates by high concentrations of H06 serum (Fig. 12) . Thus, sf-HCVcc particles showed similar susceptibility to neutralizing antibodies in chronic phase patient serum as HCVcc.
To confirm these observations, we next neutralized SA13(5a) and sf-SA13(5a) with a genotype 5a chronic-phase patient serum (SA3 ). These viruses showed similar neutralization profiles, with IC 50 values of 1/928 for SA13(5a) and 1/654 for sf-SA13(5a) as well as high neutralization rates by high concentrations of SA3 serum (Fig. 13A ).
Finally, we tested a panel of monoclonal antibodies (AR1B and AR2A-5A) targeting defined conformational epitopes in E1E2 and E2 (Law et al., 2008; Giang et al., 2012) , against SA13(5a) and sf-SA13(5a). AR1B was the least efficient for both viruses without reaching a top plateau (Fig. 13B) . AR2A-5A neutralized SA13(5a) and sf-SA13(5a) with similar concentration-response profiles, with IC 50 values ranging from 0.33 to 0.53 μg/mL for SA13(5a) and 0.19-1.56 μg/mL for sf-SA13(5a); for both viruses complete neutralization was observed at high antibody concentrations (Fig. 13C-F) . This further supports that sf-HCVcc have similar sensitivity to neutralizing antibodies as HCVcc. In addition, these findings suggest that sf-HCVcc and HCVcc do not show major differences regarding conformation of E1 and E2.
Discussion
In this study, we describe the generation and characterization of genotype 1-6 serum-free HCVcc particles, using AEM to culture infected Huh7.5 hepatoma cells. Compared to HCVcc, sfHCVcc showed similar biological properties but increased infectivity titers and a homogenous single-peak density profile. These unique characteristics, as well as the reduced concentration of non-HCV proteins in serum-free culture supernatants, are expected to facilitate generation of purified and concentrated virus stocks, required for vaccine development and biophysical studies of HCV particle composition (Gastaminza et al., 2010; Merz et al., 2010; Catanese et al., 2013; Akazawa et al., 2013) . Further, the developed serum-free culture conditions might reduce the risk of contamination with adventitious microbial Fig. 5 . The sf-HCVcc particles of genotype 1-6 displayed an altered density profile with a single infectivity peak. Of the virus stocks described in Fig. 2 , 10 mL HCVcc supernatant taken from the last harvest of DMEMþ 10% FBS culture supernatant (black line) or 10 mL sf-HCVcc supernatant taken after 48 h of AEM culture (gray, dotted line) was concentrated and layered on top of a pre-formed 10-40% iodixanol gradient and subjected to ultracentrifugation as described in "Materials and methods" section. Fractions were collected from the bottom of the gradients and analyzed by infectivity titration and by density determination as described in "Materials and methods" section. The HCV Core-E2 sequences of all virus stocks used were determined by direct sequencing. Compared to the plasmid sequence, sf-H77(1a) and H77(1a) had acquired the previously described amino acid change Y361H (Gottwein et al., 2009 ), estimated to be present in 50% of viral genomes. The sf-J4(1b) had acquired amino acid changes T578A and D584G, estimated to be present in the majority of viral genomes. Relative recovery per fraction (%) was calculated by relating the amount of infectious virus detected in each fraction to the total amount of infectious virus collected, and is plotted against the density determined for each fraction. 6 IU HCV RNA of SA13(5a) (black bars) and sf-SA13(5a) (gray bars), using monoclonal α-ApoE (1D7) and control mouse IgG1κ (1D1) as described in "Materials and methods" section. Amounts of HCV RNA (IU) were determined in the immunoprecipitated fractions using TaqMan PCR as described in "Materials and methods" section. RNA titers are shown as the mean of two replicates with SEM. agents in future vaccine antigen preparations (WHO, 1998; Houghton et al., 2013) . Efficient production of HCVcc has primarily been achieved in the continuous hepatoma cell line Huh7 and derived cell lines, such as Huh7.5 cells (Steinmann and Pietschmann, 2013; Lohmann and Bartenschlager, 2014) . Due to their increased permissiveness to infection with recombinant HCV, Huh7.5 cells were previously used for cell culture adaptation and growth of HCV genotype 1-6 recombinants used in this study (Lindenbach et al., 2005; Gottwein et al., 2007; Scheel et al., 2008; Jensen et al., 2008; Gottwein et al., 2009 ). According to WHO recommendations, a wide range of continuous cell lines are now considered as suitable substrates for production of various medicinal substances if certain requirements are met (WHO, 1998) . These requirements include use of well-characterized cell banks, use of suitable manufacturing procedures aiming at a high degree of purification of the end product, and thorough characterization of the end product (WHO, 1998) . Thus, Huh7.5 cells could potentially be characterized to comply with these recommendations, allowing their use for vaccine development. Huh7 derived cell lines have typically been subjected to long-term passage using serum-containing growth medium and animal-derived trypsin. According to WHO recommendations, animal derived products should be reduced or eliminated from cell cultures used for production of medicinal substances due to risk of contamination with adventitious microbial agents (WHO, 1998) . In this study, we describe a method for production of sf-HCVcc, thus avoiding the use of trypsin and bovine serum during the virus production phase. To further reduce presence of animal-derived components in sf-HCVcc producing cell culture, it might be possible to culture Huh7.5 cells in serumfree medium (Nakabayashi et al., 1982) , prior to sf-HCVcc production. Alternatively, based on recently generated knowledge on host-factors required for HCV infection, it might be possible to engineer cell lines already approved for vaccine development with susceptibility to HCV infection (Narbus et al., 2011; Costa et al., 2012; Kambara et al., 2012; Vogt et al., 2013; Sourisseau et al., 2013; Frentzen et al., 2014) . However, this might be a cumbersome process and might require re-approval of the modified cell-line. Of note, most genotype 1-6 recombinants used in this study (Lindenbach et al., 2005; Gottwein et al., 2007; Scheel et al., 2008; Jensen et al., 2008; Gottwein et al., 2009 ) contained adaptive mutations conferring efficient growth in Huh7.5 cells; for HK6a(6a) cell culture adaptive mutations localized to the envelope proteins. In addition, in this study H77(1a) and J4(1b) polyclonal virus stocks Fig. 8 . Huh7.5 cells cultured in DMEMþ 10% FBS or AEM showed similar surface expression of HCV co-receptors. Huh7.5 cells were incubated for 3 h in DMEM þ10% FBS or AEM and subsequently prepared for flow cytometry analysis as described in "Materials and methods" section. Cell surface expression of HCV co-receptors was determined using antibodies against (A) CD81, (B) LDLr, (C) SR-BI and (D) claudin-1 as described in "Materials and methods" section. Phycoerythrin (PE) signals were recorded on a BD FACSCalibur flow cytometer. Histograms show the co-receptor surface expression in cells cultured in DMEM þ 10% FBS (dark blue) or AEM (light blue) compared to unstained cells (black and gray, respectively).
had acquired putative cell culture adaptive mutations in the envelope proteins. In future studies, it will be of relevance to develop a panel of genotype 1-6 recombinants without envelope mutations, thus not differing from naturally occurring isolates.
Recently, proof-of-concept for immunogenicity of genotype 2a HCVcc was obtained, since immunization of mice resulted in induction of HCV neutralizing antibodies (Akazawa et al., 2013; Houghton et al., 2013; Gottwein and Bukh, 2013) . This underlines the potential of inactivated HCVcc particles as future vaccine antigens. However, HCVcc used for immunizations were grown in cell culture medium supplemented with 2% FBS (Akazawa et al., 2013) , even though the authors had previously reported development of serum-free cultures for genotype 2a recombinants JFH1 and J6/JFH1, using growth medium DMEM/F-12 supplemented with Insulin-Transferrin-Selenium-X (Akazawa et al., 2011) . In contrast to our study, infectivity titers and specific infectivity of 2a virus from such serum-free cultures were apparently only equal to or lower than titers of viruses from serum-supplemented cultures (Akazawa et al., 2011) . In addition, serum-free 2a HCVcc showed a similar density profile as 2a HCVcc derived from serum-containing cell culture, following sucrose gradient ultracentrifugation (Akazawa et al., 2011) . These differences between previously produced serum-free 2a HCVcc (Akazawa et al., 2011 ) and sf-HCVcc described in this study are most likely due to the different culture media used and/or other differences in experimental conditions.
We describe establishment of serum-free cell cultures producing HCV particles of prototype strains of genotypes 1-6 with favorable biophysical and biological characteristics (Figs. 2 and 5 and Table 1 ) (Gottwein et al., 2009; Bukh et al., 2010) . Supernatant infectivity titers of sf-HCVcc were 0.6-2.1 log 10 FFU/ml higher than titers of HCVcc (Table 1 and Fig. 2) (Gottwein et al., 2009) . Of the panel of previously developed HCVcc recombinants (Gottwein et al., 2009 ), SA13(5a) showed the highest infectivity titers ($ 5 log 10 FFU/ml). Infectivity titers of 46 log 10 FFU/ml, as observed for sf-SA13(5a) ( Table 1 and Fig. 2F and 3A) , are among the highest infectivity titers reported to date for cell culture grown HCV (Russell et al., 2008; Dhillon and Witteveldt, 2010; Pokrovskii et al., 2011; Liu et al., 2012; Jiang and Luo, 2012; Horwitz et al., 2013) . Furthermore, recombinants with relatively low infectivity titers, such as J4(1b) and ED43(4a) Gottwein et al., 2009) , yielded significantly increased infectivity titers, when grown under serum-free conditions (Table 1 and Fig. 2B and E) . Genotype 1b is considered to be the most prevalent genotype worldwide and in certain countries, such as Egypt, genotype 4a has a prevalence of up to 15%; thus genotype 4a sf-HCVcc might prove to be an important antigen for vaccine trials (Abdo and Lee, 2004; Simmonds et al., 2005) . The reason why serum-free culture conditions resulted in increased infectivity titers remains to be fully elucidated. Our studies indicated that increased infectivity in AEM cultures was not due to (i) avoiding stress related to cell splitting (Fig. 3A) , (ii) changes in Huh7.5 cell viability or proliferation (Fig. 3B) or (iii) increased stability of sf-HCVcc (Fig. 3C  and D) . While in S29 cells, serum-free culture conditions resulted in reduction of viral replication/translation, they increased viral release and specific infectivity, possibly contributing to the higher infectivity titers observed (Fig. 4) .
Specific infectivities were generally higher for sf-HCVcc than for HCVcc as observed in both Huh7.5 cell cultures (Table 1) and S29 cell cultures (Fig. 4) . This is in line with previous reports that HCVcc fractions with the highest specific infectivity had a buoyant density between 1.09 and 1.10 g/mL (Lindenbach et al., 2005) , similar to the density of the majority of infectious sf-HCVcc particles (Fig. 5) . Higher specific infectivity might be due to absence of serum, which might have non-specific neutralizing or inhibitory activity; alternatively, less immature viral particles might be produced using the developed culture conditions. Furthermore, in our serum-free cultures, supernatants with high infectivity titers could typically be harvested for a prolonged period of time compared to DMEM þ10% FBS cultures (Figs. 1-4) . For example, for SA13(5a), high-titer supernatants could typically be harvested at 2-3 subsequent time points in DMEM þ10% FBS cultures, whereas in serum-free cultures, high-titer supernatants could be harvested at 4-6 subsequent time points (Figs. 2F and 3A) . This further increased the yield of infectious virus that could be harvested from serum-free cultures.
In contrast to HCVcc, sf-HCVcc displayed a homogeneous density distribution with a single peak of infectious virus at densities of $ 1.10 g/mL, following iodixanol gradient ultracentrifugation (Fig. 5) . We believe that the density profile of sf-HCVcc might allow more effective density-based purification and concentration using ultracentrifugation and gel chromatography, since a single fraction, containing the majority of infectious virus, could be collected. Density changes were previously observed for HCVcc without hypervariable region 1 (HVR1) (Bankwitz et al., 2010; Prentoe et al., 2011) , HCVcc with a specific E2 mutation (Zhong et al., 2006; Grove et al., 2008; Gastaminza et al., 2010) and for HCV recovered from HCVcc-infected chimpanzees and uPA-SCID mice engrafted with human liver cells (Lindenbach et al., 2006) . These density changes were suggested to be due to differences in lipoprotein association (Lindenbach et al., 2006; Zhong et al., 2006; Grove et al., 2008; Bankwitz et al., 2010; Prentoe et al., 2011) . We showed that sf-SA13(5a) could be neutralized as efficiently as its HCVcc counterpart by a monoclonal α-ApoE antibody and polyclonal α-ApoE IgG (Fig. 6A and data not  shown) . Further, immunoprecipitation of sf-SA13(5a) and SA13(5a) showed similar efficacy (Fig. 6B) . These data indicate that HCVcc and sf-HCVcc do not show major differences in association to ApoE, and thus possibly to lipoproteins (Yamamoto et al., 2011) . Therefore, further studies will be required to elucidate the cause for the observed density shift (Fig. 5) . Preliminary studies indicated a decrease in intracellular lipid content in serum-free Fig. 9 . The sf-HCVcc density profile was maintained after in vitro incubation with serum. The sf-SA13(5a) was mixed 1:1 with either 100% FBS, DMEM þ 10% FBS, DMEM, AEM, 100% human serum or sterile filtered cell culture conditioned medium (DMEMþ 10% FBS harvested after 48 h culture on naïve Huh7.5 cells) and incubated for 6 h at 37 1C. Mixes were layered on top of a pre-formed 10-40% iodixanol gradient, and subjected to ultracentrifugation as described in "Materials and methods" section. Fractions were collected from the bottom of the gradients and analyzed by infectivity titration and by density determination as described in "Materials and methods" section. Relative recovery per fraction (%) was calculated by relating the amount of infectious virus detected in each fraction to the total amount of infectious virus collected, and is plotted against the density determined for each fraction.
cultures (data not shown). However, determination of expression levels of genes involved in lipid production or of lipid/lipoprotein composition of HCVcc versus sf-HCVcc (Merz et al., 2010) was considered outside the scope of this study. FBS to the indicated concentrations. Specified antibody (open symbols) or control antibody (closed symbols) dilutions were added to Huh7.5 cells, plated the previous day onto poly-D-lysine coated 96-well plates and incubated for 1 h. HCVcc (black circles) were diluted in DMEM þ10% FBS and sf-HCVcc (gray squares) were diluted in AEMþ10% FBS and added to cultures. After 6 h incubation, antibody-virus mixes were removed and DMEM þ10% FBS was added. Cells were fixed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well was determined by automated counting as described in "Materials and methods" section. The HCV Core-E2 sequences of all virus stocks used were determined by direct sequencing. Sequences were identical for HCVcc and sf-HCVcc of the same recombinant. Compared to the plasmid sequence, H77(1a) viruses had acquired amino acid change I348S and J4(1b) had acquired amino acid change V710L, both estimated to be present in the majority of viral genomes. The % blocking was calculated by relating counts of experimental wells to the mean count of six replicate wells with untreated control virus. Data points are means of three replicates with SEM (error bars). Following logarithmic transformation of X-values, variable-slope sigmoidal dose-response curves were fitted [Y ¼ Bottomþ (TopBottom)/(1 þ10 (Log10EC50 À X)HillSlope )]. "Bottom" was constrained to "0". B max values, the Y values at the top plateaus of the fitted curves, are shown for HCVcc (black) and sfHCVcc (gray). No curve could be fitted to data points obtained for sf-HK6a(6a) in SR-BI blocking experiments. ND, not determinable.
previously described serum-free HCVcc were more susceptible to blocking of CD81 and SR-BI and to neutralization by a monoclonal antibody targeting E2 (AP33) (Akazawa et al., 2011) . Of note, in this study biological assays were carried out in AEM supplemented with FBS, which was required for viral infection, but apparently did not alter composition of sf-HCVcc LVP (Figs. 7 and 9 ). When blocking CD81 and SR-BI, we did not observe major differences between sfHCVcc and HCVcc (Fig. 10) . Even though sf-HCVcc of certain genotypes showed slightly lower dependency on LDLr and slightly higher dependency on clathrin mediated endocytosis than their HCVcc counterparts (Figs. 10 and 11 ), overall our findings suggested that sf-HCVcc relied on similar routes of entry as HCVcc. In the future, it will be of interest to further investigate the small differences observed for LDLr usage and dependency on clathrin mediated endocytosis using different blocking antibodies and alternative methods of inhibition such as RNA interference. We further confirmed previous results showing that HCVcc of genotype 1-6 showed similar dependency on CD81 (Gottwein et al., 2009) . Previously, we reported that blocking SR-BI had a similar effect on genotype 1-6 HCVcc entry (Gottwein et al., 2009) . However, in this study and another recent study by our group (Prentoe et al., 2014) , using a different blocking antibody, we Fig. 11 . Effect of chlorpromazine treatment on HCVcc and sf-HCVcc entry. (A-G) Chlorpromazine was diluted in DMEMþ 10% FBS to the concentrations indicated and then added to Huh7.5 cells, plated the previous day onto poly-D-lysine coated 96-well plates, and incubated for 30 min. HCVcc (black bars) were diluted in DMEM þ 10% FBS and sf-HCVcc (gray bars) were diluted in AEMþ10% FBS and added to cultures. After 6 h incubation, chlorpromazine-virus mixes were removed and DMEM þ10% FBS was added. Cells were fixed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well was determined by automated counting as described in "Materials and methods" section. The HCV Core-E2 sequences of all virus stocks used were determined by direct sequencing. Sequences were identical for HCVcc and sf-HCVcc of the same recombinant. Compared to the plasmid sequence, H77(1a) viruses had acquired amino acid change I348S and J4(1b) had acquired amino acid change V710L, both estimated to be present in the majority of viral genomes. The % blocking was calculated by relating counts of experimental wells to the mean count of six replicate wells with untreated control virus. Data points are means of three replicates with SEM (error bars).
n ,Values o0. (H) Chlorpromazine was diluted in DMEM þ 10% FBS to the concentrations indicated and then added to Huh7.5 cells, plated the previous day in poly-D-lysine coated 96-well plates. Cells were incubated for 6 h before chlorpromazine was removed and DMEMþ 10% FBS was added. A cell viability assay was carried out on cells incubated for 6 h with chlorpromazine and on control cultures as described in "Materials and methods" section (0 h post treatment; dashed bars). An additional cell viability assay was carried out on chlorpromazine treated-and control cultures 48 h post treatment (white bars). The % viability was calculated by relating absorbance at 490 nm determined for chlorpromazine treated cultures to the mean absorbance of three replicate untreated cultures. Bars represent the means of three replicates with SEM.
found differential sensitivity of genotype 1-6 HCVcc to SR-BI blocking. Single E2 mutations in culture adapted JFH1(2a) were reported to cause reduced dependency on SR-BI (Grove et al., 2008; Dhillon and Witteveldt, 2010) . Further studies are required to elucidate if the E2 mutations present in HK6a(6a) and J4(1b) HCVcc virus stocks mediated reduced dependency on SR-BI. For genotype 1-6 HCVcc, we also observed small but consistent differences regarding dependency on LDLr (Fig. 10) . Whereas dependency on LDLr for entry has been shown for JFH1(2a) (Owen et al., 2009; Albecka et al., 2012) and was recently shown for H77(1a), J6(2a) and S52(3a) HCVcc (Prentoe et al., 2014) , this study is the first to show dependency on LDLr for J4(1b), ED43(4a), SA13(5a) and HK6a(6a) HCVcc. In future studies, also involving recombinants of additional isolates of each genotype, it will be of interest to investigate if different genotypes, subtypes or isolates differ regarding receptor usage. Compared to HCVcc, sf-HCVcc showed similar sensitivity to neutralization by chronic phase patient sera and human monoclonal antibodies targeting conformational epitopes in E1E2 and E2 (Figs. 12 and 13) . These results suggest that sf-HCVcc resemble Fig. 12 . HCVcc and sf-HCVcc show similar sensitivity to neutralization with genotype 1a chronic-phase patient serum. Genotype 1a serum H06 was diluted in DMEM þ10% FBS as indicated. HCVcc (black circles) were diluted in DMEMþ 10% FBS and sf-HCVcc (gray squares) were diluted in AEMþ10% FBS, mixed with H06 serum dilutions and incubated 1 h at 37 1C. Virus-serum mixes were added to Huh7.5 cells, plated the previous day onto poly-D-lysine coated 96 well plates. After 6 h incubation, virus-serum mixes were removed and DMEM þ 10% FBS was added. Cells were fixed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well was determined by automated counting as described in "Materials and methods" section. The HCV Core-E2 sequences of all virus stocks used were determined by direct sequencing. Sequences were identical for HCVcc and sf-HCVcc of the same recombinant. Compared to the plasmid sequence, H77(1a) viruses had acquired amino acid change I348S and J4(1b) had acquired amino acid change V710L, both estimated to be present in the majority of viral genomes. The % neutralization was calculated by relating counts of experimental wells to the mean count of six replicate wells with untreated control virus. Data points are means of three replicates with SEM (error bars). Following logarithmic transformation of X-values, variable-slope sigmoidal dose-response curves were fitted [Y ¼ Bottomþ (Top-Bottom)/(1 þ 10 (Log10EC50 À X)HillSlope )].
"Bottom" was constrained to "0" for all curves. "Top" was constrained to "100" for all curves in all panels except D; for these curves, median inhibitory concentrations (IC 50 ) were calculated (black for HCVcc and gray for sf-HCVcc). ND, not determinable.
HCVcc regarding epitope exposure and conformation, of importance for vaccine development using sf-HCVcc as antigen.
In conclusion, we have established a method allowing for robust production of genotype 1-6 sf-HCVcc with favorable biological and biophysical characteristics. Serum-free culture apparently reduced viral replication/translation but enhanced viral release and specific infectivity. Sf-HCVcc had increased infectivity titers compared to HCVcc, and compared to serum-free HCVcc reported previously, thus contributing to an increased yield of infectious virus from infected cell cultures. Furthermore, sf-HCVcc displayed a homogeneous density distribution. Together with a reduced concentration of non-HCV proteins in supernatants from serum-free cultures, these features are expected to facilitate viral purification and concentration required for vaccine production and morphological analysis of HCV particles. Biologically, sf-HCVcc particles resembled their HCVcc counterparts regarding association to ApoE, routes of viral entry and sensitivity to neutralizing antibodies. Thus, sf-HCVcc particles could prove important as antigens in a prophylactic HCV vaccine against all six epidemiologically important HCV genotypes. To this aim future studies are required, focussing on establishment of large-scale sf-HCVcc production as well as efficient purification, concentration and inactivation. Finally, it will be of great interest to test immunogenicity of genotype 1-6 sf-HCVcc in small animal models.
Materials and methods

Huh7.5 cell culture and infection with HCV recombinants
Human hepatoma Huh7.5 cells were cultured in culture flasks (Nunc) in DMEM (Gibco/Invitrogen) supplemented with 10% fetal bovine serum (FBS, [Sigma] ), penicillin 100 U/mL and streptomycin 100 mg/mL (Gibco/Invitrogen), referred to as DMEM þ10% FBS. Cells were kept sub-confluent and split every 2-3 days. For splitting, cells were washed in PBS (Invitrogen) and detached using trypsin (Sigma-Aldrich). For serum-free cultures, cells were plated in DMEM þ 10% FBS. When cells were 80% confluent, DMEM þ10% FBS was removed, cells were washed in PBS and adenovirus expression medium (AEM, [Gibco/Invitrogen]) supplemented with penicillin 100 U/mL and streptomycin 100 mg/mL, referred to as AEM, was added without splitting the cells. Every 2-3 days, supernatant was removed and fresh AEM was added to the cells. Huh7.5 cell cultures were maintained at 37 1C and 5% CO 2 . Fig. 13 . SA13(5a) and sf-SA13(5a) show similar susceptibility to genotype 5a patient serum and human monoclonal antibodies. (A) Genotype 5a chronic phase serum SA3 or (B-F) monoclonal antibodies AR1B and AR2A-5A were diluted in DMEMþ 10% FBS as indicated. HCVcc (black circles) were diluted in DMEM þ 10% FBS and sf-HCVcc (gray squares) were diluted in AEMþ 10% FBS, mixed with SA3 serum, AR1B or AR2A-5A antibody dilutions and incubated 1 h at 37 1C. Virus-serum or virus-antibody mixes were added to Huh7.5 cells, plated the previous day in poly-D-lysine coated 96 well plates. After 6 h incubation, virus-serum or virus-antibody mixes were removed and DMEM þ10% FBS was added. Cells were fixed 48 h post infection and stained, and the number of single HCV NS5A positive cells per well was determined by automated counting as described in "Materials and methods" section. The % neutralization was calculated by relating counts of experimental wells to the mean count of six replicate wells with untreated control virus. Data points are means of three replicates with SEM (error bars). Following logarithmic transformation of X-values, variable-slope sigmoidal dose-response curves were fitted [Y ¼ Bottomþ (Top-Bottom)/(1 þ 10 (Log10EC50 À X)HillSlope )]. "Bottom" was constrained to "0" for all curves. "Top" was constrained to
"100" for all curves. Median inhibitory concentrations (IC 50 ) were calculated (black for HCVcc and gray for sf-HCVcc).
Generation of HCVcc virus stocks
For generation of HCVcc and sf-HCVcc virus stocks, Huh7.5 cells cultured in DMEMþ 10% FBS at 80% confluency were infected at a multiplicity of infection (MOI) of 0.003 using 1st or 2nd viral passage stocks of the following HCVcc intra-and intergenotypic recombinants: H77C/JFH1 V787A,Q1247L (referred to as H77(1a)), J4/JFH1 F886L,Q1496L (J4(1b)), J6/JFH1 (J6(2a)), S52/JFH1 I787S,K1398Q (S52(3a)), ED43/JFH1 T827A,T977S (ED43(4a)), SA13/JFH1 A1022G,K1119R (SA13(5a)), and HK6a/JFH1 F350S,N417T (HK6a(6a)) (Lindenbach et al., 2005; Gottwein et al., 2007; Scheel et al., 2008; Jensen et al., 2008; Gottwein et al., 2009 ). The % infection was monitored by HCVspecific immunostaining as described below. For generation of HCVcc virus stocks, cells were maintained in DMEM þ 10% FBS; supernatants were harvested every 2-3 days, when cells were split, until % of infected cells declined (Gottwein et al., 2007) , as detected by immunostaining. High-titer stocks, collected at the peak of viral infection, were used for further experiments. Stocks with relatively low peak titers were concentrated using Amicon 100 kDa centrifugation filters (Millipore). For generation of sf-HCVcc virus stocks, DMEM þ 10% FBS cell cultures with 40-80% HCV infected cells were washed with PBS and AEM was added. Cells were maintained in AEM, and supernatants were harvested every 2-3 days, when AEM was exchanged, for up to 29 days. Supernatants were sterile filtered and stored at À80 1C. The HCV Core-E2 sequences of all virus stocks used for further experiments were determined by direct sequencing (described below). Sequences were identical to the plasmid sequence unless otherwise indicated in respective figure and table legends.
Evaluation of HCV infected cell cultures
Spread of HCV recombinants in cell cultures was monitored by HCV NS5A immunostaining. Cells plated onto chamber slides (Nunc) the previous day were fixed for 10 min in ice-cold acetone (Sigma-Aldrich) and washed twice with PBS and twice with PBS þ 0.1% Tween-20 (Sigma-Aldrich). Cells were stained for HCV NS5A using primary anti-NS5A antibody 9E10 (Lindenbach et al., 2005) at 1:1000 dilution in PBS þ 1% bovine serum albumin (BSA, [Roche Applied Science]) þ 0.2% skim milk (PBS/BSK) for two hours at room temperature. Cells were washed twice with PBS and twice with PBS þ0.1% Tween-20 and stained using secondary antibody Alexa Fluor 594-conjugated goat anti-mouse IgG (Hþ L) (Invitrogen) at 1:500 dilution and Hoechst 33342 (Invitrogen) at 1:1000 dilution in PBS þ0.1% Tween-20. Cells were washed twice in PBS, before being covered by Fluoromount-G (SouthernBiotech) and a cover-slip.
Culture supernatant infectivity titers were determined as FFU/mL. Huh7.5 cells, plated at 6000 cells/well onto poly-D-lysine coated 96-well plates (Nunc) the day before, were infected with serially-diluted supernatants (lowest dilution 1:2). Forty-eight hours after infection, cells were fixed in ice-cold methanol and washed twice with PBS þ0.1% Tween-20 before being incubated with 3% H 2 O 2 for five minutes at room temperature. Cells were washed twice with PBS þ0.1% Tween-20 and HCV NS5A was immunostained with primary anti-NS5A antibody 9E10 at 1:1000 dilution in PBS/BSK at 4 1C. The next day, cells were washed twice with PBS þ 0.1% Tween-20 and stained using secondary antibody ECL anti-mouse IgG horseradish peroxidase (HRP)-linked whole antibody (GE Healthcare Amersham) at 1:300 in PBS þ0.1% Tween-20 for 30 min at room temperature before being visualized by 30 min incubation at room temperature with a DAB substrate kit (Dako). FFU were counted automatically using an ImmunoSpot series 5 UV analyzer (CTL Europe GmbH) with the customized software as described previously (Gottwein et al., 2010) . Lower limit of detection was calculated for each 96-well plate as the mean of at least 6 negative wells plus 3 standard deviations plus 3. Upper limit of detection was set to 200 FFU/well as this was within the linear range of test dilution series and comparable with manual determinations .
For determination of HCV RNA titers in culture supernatant, RNA was extracted from 200 μL supernatant using the Total Nucleic Acid Isolation Kit (Roche Applied Science); titers were determined by TaqMan real-time PCR as previously described (Gottwein et al., 2007) . HCV Core titers in culture supernatant were determined using the ARCHITECT HCV Ag assay (Abbott).
Direct sequencing of cell culture-derived HCV HCV RNA was purified from 200 μL cell culture supernatant using the High Pure Viral Nucleic Acid Kit (Roche Applied Science). Overall, reverse transcription, 1st round PCR and 2nd round nested PCR were carried out as previously described (Gottwein et al., 2007) . Primers used to generate cDNA and PCR amplicons spanning the Core-E2 region have been previously reported for H77(1a) and ED43(4a) ; J4(1b) and HK6a(6a) (Gottwein et al., 2009 ), J6(2a) and S52(3a) (Gottwein et al., 2007) ; as well as SA13(5a) . Direct sequencing of amplicons was carried out by Macrogen Europe.
Single-cycle virus production assay in S29 cells
Overall, S29 cell experiments were carried out as previously described (Serre et al., 2013) . Briefly, 400,000 CD81-deficient S29 cells (Russell et al., 2008) were plated in 6-well plates 24 h before transfection. In vitro HCV RNA transcripts of SA13(5a) as well as of positive control (J6(2a)) and of negative control (J6(2a)-GND) (Lindenbach et al., 2005) were generated using T7 RNA polymerase (Promega) for 2 h at 37 1C, DNAse treated using DNA RQ1 DNAse (Promega) and purified using RNeasy kit (Qiagen). HCV RNA transcripts (2.5 mg) were mixed with 5 mL Lipofectamine 2000 (Invitrogen) in 500 mL serum-free Opti-MEM (Gibco/Invitrogen). S29 cells were incubated with transfection complexes for 4 h in Opti-MEM. Following transfection, Opti-MEM was replaced by either DMEM þ10% FBS or AEM. S29 cells were collected at 4, 24, 48 and 72 h post transfection and prepared for determination of intracellular HCV Core and infectivity titers as previously described (Serre et al., 2013) . Culture supernatants were collected at 24, 48 and 72 h post transfection for determination of extracellular HCV Core and infectivity titers. Infectivity titers were determined as described above, while Core titers were determined using the ARCHITECT HCV Ag assay (Abbott).
Equilibrium density gradient ultracentrifugation
Semi-continuous 10-40% iodixanol gradients were prepared by layering 2.5 mL of 40%, 30%, 20% and 10% OptiPrep (iodixanol; Sigma-Aldrich) on top of each other as described previously (Prentoe et al., 2011) . HCVcc containing supernatants were either loaded directly on top of the gradient, or concentrated using Amicon 100 kDa centrifugation filters before loading. A final volume of $ 250 mL was loaded for all samples. The samples were ultracentrifugated at 151,000 Â relative centrifugal force (RCF) for 18 h at 4 1C using a Beckman SW-41 rotor mounted in a Beckman XL-70 ultracentrifuge. After centrifugation, fractions of $ 550 mL were collected from the bottom of the tube and 400 mL portions were weighed (model SI-114; Denver Instruments) to determine fraction densities. Fraction infectivity titers were determined as described above. Iodixanol containing fractions were diluted to contain r10% iodixanol before titration.
Receptor-, endocytosis-and neutralization assays
For receptor blocking assays we used Purified Mouse AntiHuman CD81 primary antibody (JS-81) and Purified Mouse IgG1κ isotype control (MOPC-21) (both BD Biosciences); Purified Goat Anti-human LDLr polyclonal antibody (AF2148) and Normal Goat IgG control (AB108C) (both R&D Systems); Anti-SR-BI primary antibody (C16-71) and control antibody (D) were previously described (Catanese et al., 2007) . For HCVcc neutralization, we used chronic-phase serum from patient H taken 29 years after acute infection (H06 ) and chronic-phase serum from a genotype 5a infected patient (SA3 ) as well as a panel of monoclonal antibodies AR1B and AR2A-5A, which were previously described (Giang et al., 2012; Law et al., 2008) . For ApoE neutralization we used a mouse monoclonal primary antibody (1D7) blocking the ApoE receptor binding site, and mouse IgG1κ (1D1) control antibody previously described (Weisgraber et al., 1983) . For inhibition of clathrinmediated endocytosis, we used chlorpromazine hydrochloride (Calbiochem).
Huh7.5 cells were plated at 7000 cells/well onto poly-D-lysine coated 96-well plates. On the following day, for receptor-blocking assays, antibodies were diluted in DMEM þ10% FBS as specified and added to cells for 1 h. For chlorpromazine assays, chlorpromazine was diluted in DMEM þ10% FBS as specified and added to cells for 30 min. HCVcc was diluted in DMEM þ10% FBS, whereas sf-HCVcc was diluted in AEM with FBS concentration adjusted to 10%. Virus dilutions were added to the cells incubated with blocking antibodies or chlorpromazine. Cell cultures were incubated for an additional 6 h.
For HCV neutralization assays, chronic-phase HCV sera, or AR1B and AR2A-5A monoclonal antibodies were diluted in DMEM þ10% FBS as specified and mixed with either HCVcc or sf-HCVcc diluted as for receptor blocking assays. Patient serumvirus or antibody-virus mixes were incubated for 1 h, before being added to cells. Cell cultures were incubated for 6 h. For ApoE neutralization, 1D7 and 1D1 monoclonal antibodies were diluted in DMEM þ 10% FBS as specified and mixed with either HCVcc or sf-HCVcc, diluted in DMEM þ10% FBS. Antibody-virus mixes were incubated for 30 min, before being added onto cells. Cell cultures were incubated for 3 h.
For blocking and neutralization assays, after 3 or 6 h incubation as indicated above, the cells were washed in PBS and DMEM þ10% FBS was added to all cultures. Cells were incubated and fixed 48 h post infection in ice-cold methanol and HRPstained for HCV NS5A as described above. Single HCV NS5A positive cells were counted automatically using an ImmunoSpot series 5 UV analyzer (CTL Europe GmbH) with customized software as described previously Gottwein et al., 2011) . The % blocking and neutralization were calculated by relating counts of experimental wells to the mean count of six replicate wells with untreated control virus. For receptor blocking and neutralization assays, following logarithmic transformation of X-values, variable-slope sigmoidal dose-response curves [Y ¼ Bottom þ(Top-Bottom)/(1 þ 10 (Log10EC50 À X)HillSlope )] were fitted to the data using GraphPad Prism 6.0. For receptor blocking and neutralization assays "Bottom" was constrained to "0". For neutralization assays, "Top" was constrained to "100", when appropriate, as indicated in Figure legends , and median inhibitory concentrations (IC 50 ) were calculated using GraphPad Prism 6.0. For receptor blocking assays, maximum blocking rates (B max ), the Y values at the top plateaus of the fitted curves, were calculated using GraphPad Prism 6.0.
HCV immunoprecipitation using anti-ApoE antibody
Immunoprecipitation was done using the ApoE-specific antibody 1D7 and isotype-matched control antibody 1D1 as previously described (Prentoe et al., 2014) . Briefly, 50 ml of magnetic-bead slurry was washed in antibody binding buffer (immunoprecipitation kit; Dynabeads Protein G; 100.070D; Invitrogen) and incubated on a shaker with 5 mg antibody in 50 ml antibody binding buffer for 20 min at room temperature. The beads were subsequently washed two times in washing buffer and incubated with 10 6 IU of the virus in 200 ml of DMEM þ10% FBS on a shaker for 1 h at room temperature. The beads were removed and washed three times in 200 ml of washing buffer prior to elution in 50 ml according to the manufacturer's instructions. HCV RNA was extracted from the complete eluate and measured in duplicates as previously described (Gottwein et al., 2007) .
Cell viability and proliferation assays
For determination of Huh7.5 cell viability in DMEM þ 10% FBS versus AEM, we plated 6000 cells per well of poly-D-lysine coated 96-well plates in DMEM þ10% FBS. The following day, medium was removed and cells were incubated in DMEMþ 10% FBS or AEM for 48 h. Then, cell viability was determined using the CellTiter 96 s AQueous One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions. The % viability was calculated by relating absorbance at 490 nm determined for 10 AEM cultures to the mean absorbance of 10 replicate DMEMþ 10% FBS cultures. For determination of chlorpromazine cytotoxicity, chlorpromazine was diluted in DMEM þ10% FBS as specified and then added to 6000 Huh7.5 cells/well, plated the previous day in poly-D-lysine coated 96-well plates. Cells were incubated for 6 h before chlorpromazine was removed and DMEM þ 10% FBS was added. Cell viability was determined 6 and 48 h post-treatment using the CellTiter 96 s AQueous One Solution Cell Proliferation Assay kit.
The % viability was calculated by relating absorbance at 490 nm determined for chlorpromazine treated cultures to the mean absorbance of at least three replicate untreated cultures. For determination of Huh7.5 cell proliferation in DMEMþ 10% FBS versus AEM, we used the BrdU cell proliferation kit (Millipore). Cells were plated in poly-D-lysine coated 96-well plates at 2000 cells/well in DMEM þ 10% FBS according to the manufacturer's instructions. The following day, medium was removed and cells were incubated in DMEM þ10% FBS or AEM for 48 h. Then, cell proliferation was determined using the BrdU cell proliferation kit according to the manufacturer's instructions. The % proliferation was calculated by relating absorbance at 450 nm determined for 10 replicate AEM cultures to the mean absorbance of 10 replicate DMEM þ10% FBS cultures.
Flow cytometry
For surface staining of HCV co-receptors we used Phycoerythrin (PE) Mouse Anti-Human CD81 primary antibody (BD Biosciences, JS-81), Anti-mouse LDL R-Phycoerythrin primary antibody (R&D systems, 263123), Purified Mouse Anti-Human CLA-1 (SR-BI) primary antibody (BD Transduction Laboratories, 25/CLA-1) with PE Goat Anti-Mouse Ig secondary antibody (BD Biosciences, polyclonal 550589) and Anti-human Claudin-1 primary antibody (R&D systems, 421203) with PE Goat Anti-Rat Ig secondary antibody (BD Biosciences, polyclonal 550767). Cells were detached by treatment with a 10 mM solution of EDTA in PBS for 10 min at 37 1C. The cells were washed in PBS and resuspended in FACS buffer (PBSþ1% FBS) and 2.5 Â 10 5 cells/well were plated in a V-bottom 96-well plate. Cells were stained protected from light at 4 1C for 1 h with either α-CD81 (25 μL/well according to the manufacturer's instructions), α-LDLr (10 μg/mL in FACS buffer), α-SR-BI (5 μg/mL in FACS buffer) or α-Claudin-1 (5 μg/mL in FACS buffer). Total volume in all wells was adjusted to 50 μL using FACS buffer. After incubation, cells were washed in FACS buffer. SR-BI-and claudin-1-stained cells were stained protected from light at 4 1C for 20 min with secondary antibodies α-mouse Ig (4 μg/mL in FACS buffer) or α-rat Ig (2 μg/mL in FACS buffer). Cells were washed in FACS buffer and fixed protected from light at room temperature for 15 min using CellFix (BD Biosciences). Cells were washed and resuspended in PBS before they were analyzed on a BD FACSCalibur flow cytometer using CellQuest Pro. Data analysis was done using FlowJo flow cytometry analysis software.
